Dyne Therapeutics Stock Down 17% Amid Secondary Stock Offering

Dyne Therapeutics announced a $300 million secondary stock issue, causing its shares to drop by 17%. The company plans to use the funds to advance its development programs and build manufacturing assets. The dilution from the new capital is a concern for investors, but the biotech has positive momentum with its Duchenne muscular dystrophy treatment, zeleciment rostudirsen.